REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on HIV-Linked cancers
Disease control Recruiting nowThis phase 1 trial is testing a CAR-T cell therapy (axicabtagene ciloleucel) in 20 adults with HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to recognize and attack cancer c…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated May 26, 2026 03:35 UTC
-
New drug may keep lymphoma in check long enough for Life-Saving cell therapy
Disease control Recruiting nowThis study tests a drug called odronextamab given before CAR-T cell therapy in people with large B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this bridging therapy can control the cancer long enough for patients to successfully unde…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 03:34 UTC
-
Experimental combo aims to outsmart Hard-to-Treat lymphomas
Disease control Recruiting nowThis early-phase study tests whether combining two drugs—nivolumab (an immunotherapy that helps the immune system attack cancer) and ASTX727 (a pill that makes chemotherapy more effective)—is safe and can shrink tumors in people with B-cell lymphoma that has returned or stopped r…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:34 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 adults will receive the combination to evaluate safety, the bes…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:34 UTC
-
New hope for lymphoma patients: drug cocktail aims to control cancer without transplant
Disease control Recruiting nowThis study tests whether adding either tazemetostat or zanubrutinib to a standard two-drug therapy (tafasitamab and lenalidomide) can better control relapsed or refractory large B-cell lymphoma in people who are not eligible for a stem cell transplant. About 227 participants will…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 26, 2026 03:32 UTC
-
Radiation boost before CAR T-Cells shows promise for tough lymphoma
Disease control Recruiting nowThis study tests giving radiation therapy to all active cancer spots before CAR T-cell infusion in people with large B-cell lymphoma that has returned or not responded to treatment. The goal is to control the disease and symptoms during the wait for CAR T-cells, potentially impro…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 03:31 UTC
-
New drug combo aims to outsmart tough lymphoma
Disease control Recruiting nowThis study is for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to previous treatments. It tests a combination of two drugs: epcoritamab, which helps the immune system attack cancer cells, and ibrutinib, which blocks signals that help cance…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated May 26, 2026 03:30 UTC
-
Could a Two-Punch approach beat tough lymphoma?
Disease control Recruiting nowThis study tests whether adding the drug odronextamab before and after standard CAR T-cell therapy helps people with diffuse large B-cell lymphoma that has returned or not responded to prior treatments. About 34 adults will receive odronextamab to help their immune T-cells find a…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 26, 2026 03:30 UTC
-
New combo aims to tackle lymphoma in communities often left behind
Disease control Recruiting nowThis early-stage trial tests two oral drugs, zanubrutinib and sonrotoclax, for people with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The study focuses on Black, Hispanic, and other underrepresented groups to improve access and outcomes. Ab…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 03:29 UTC
-
Vitamin c boost: could high doses make chemo more effective for tough lymphomas?
Disease control Recruiting nowThis phase 2 trial tests whether adding high-dose intravenous vitamin C to standard chemotherapy can help treat blood cancers like lymphoma that have returned or not responded to treatment, as well as related conditions. About 80 adults will receive the combination to see if it i…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 03:27 UTC
-
New combo therapy aims to boost lymphoma remission after transplant
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy and a stem cell transplant can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatment. About 25 adults will receive epcoritamab plus chemotherapy be…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 26, 2026 03:26 UTC
-
New drug duo aims to tackle tough lymphoma
Disease control Recruiting nowThis study tests whether combining two targeted drugs, loncastuximab tesirine and mosunetuzumab, can safely and effectively treat adults with diffuse large B-cell lymphoma that has come back or stopped responding to prior therapy. The drugs work by attaching to cancer cells and e…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 03:25 UTC
-
Poop pills could help CAR t therapy work better for lymphoma patients
Disease control Recruiting nowThis study tests whether giving fecal transplants from healthy donors can repair gut damage caused by antibiotics and chemotherapy in lymphoma patients receiving CAR T-cell therapy. About 56 adults with relapsed or hard-to-treat lymphoma will be randomly assigned to receive eithe…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 03:25 UTC
-
New CAR T-Cell attack on tough blood cancers shows early promise
Disease control Recruiting nowThis early-phase study tests a new treatment called MC10029, which uses a patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells. The therapy targets a protein called BAFFR found on certain blood cancer cells. The study includes up to…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 02:48 UTC
-
Can a one-two punch after CAR t keep lymphoma away?
Disease control Recruiting nowThis study is for people with certain types of lymphoma that came back or didn't respond to treatment. After receiving CAR T-cell therapy, participants will get one or two additional drugs (mosunetuzumab and/or polatuzumab vedotin) to see if they help keep the cancer from returni…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New 5-Drug cocktail ViPOR targets Hard-to-Treat lymphomas
Disease control Recruiting nowThis study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive B-cell lymphomas that have come back or not responded to prior therapy. The goal is to see how many patients achieve co…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Smart bomb for lymphoma: targeted drug trial seeks to shrink tumors
Disease control Recruiting nowThis phase 2 trial tests whether loncastuximab tesirine can shrink tumors in 20 adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug is a targeted therapy that attaches to a protein on cancer cells and delivers a chemotherapy agent directl…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:53 UTC